Ibrutinib Outperforms Chemoimmunotherapy in CLL

Dr. Woyach shares findings from her plenary abstract, in which ibrutinib improved survival outcomes in older patients with chronic lymphocytic leukemia, compared with a standard-of-care regimen of rituximab and bendamustine.

SHARE